These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37691032)

  • 1. EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.
    Alzate JD; Mullen R; Mashiach E; Bernstein K; De Nigris Vasconcellos F; Rotmann L; Berger A; Qu T; Silverman JS; Golfinos JG; Donahue BR; Kondziolka D
    J Neurooncol; 2023 Sep; 164(2):387-396. PubMed ID: 37691032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC).
    Shuto T; Akabane A; Yamamoto M; Serizawa T; Higuchi Y; Sato Y; Kawagishi J; Yamanaka K; Jokura H; Yomo S; Nagano O; Aoyama H
    J Neurosurg; 2018 Dec; 129(Suppl1):86-94. PubMed ID: 30544291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
    Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases.
    Minniti G; Lanzetta G; Capone L; Giraffa M; Russo I; Cicone F; Bozzao A; Alongi F; Nicosia L; Fineschi G; Marchetti L; Tufo T; Bianciardi F; Esposito V; Gentile P; Paolini S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases.
    Wolf A; Donahue B; Silverman JS; Chachoua A; Lee JK; Kondziolka D
    J Neurooncol; 2017 Aug; 134(1):139-143. PubMed ID: 28536993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery.
    Siomin VE; Vogelbaum MA; Kanner AA; Lee SY; Suh JH; Barnett GH
    J Neurooncol; 2004; 67(1-2):115-21. PubMed ID: 15072456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer.
    Trifiletti DM; Romano KD; Xu Z; Reardon KA; Sheehan J
    J Neurooncol; 2015 Sep; 124(3):421-7. PubMed ID: 26093620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases.
    Atalar B; Modlin LA; Choi CY; Adler JR; Gibbs IC; Chang SD; Harsh GR; Li G; Nagpal S; Hanlon A; Soltys SG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):713-8. PubMed ID: 24054875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.
    Huang AJ; Huang KE; Page BR; Ayala-Peacock DN; Lucas JT; Lesser GJ; Laxton AW; Tatter SB; Chan MD
    J Neurooncol; 2014 Oct; 120(1):163-9. PubMed ID: 25048529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
    Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
    Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
    Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery.
    Teyateeti A; Brown PD; Mahajan A; Laack NN; Pollock BE
    Neurooncol Adv; 2021; 3(1):vdab036. PubMed ID: 33860228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    Li Y; Liu B; Connolly ID; Kakusa BW; Pan W; Nagpal S; Montgomery SB; Hayden Gephart M
    J Thorac Oncol; 2018 Jul; 13(7):1022-1027. PubMed ID: 29604399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases.
    Prabhu RS; Turner BE; Asher AL; Marcrom SR; Fiveash JB; Foreman PM; Press RH; Patel KR; Curran WJ; Breen WG; Brown PD; Jethwa KR; Grills IS; Arden JD; Foster LM; Manning MA; Stern JD; Soltys SG; Burri SH
    Neuro Oncol; 2019 Aug; 21(8):1049-1059. PubMed ID: 30828727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Tatineni V; O'Shea PJ; Ozair A; Khosla AA; Saxena S; Rauf Y; Jia X; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190312
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.
    Brown DA; Lu VM; Himes BT; Burns TC; Quiñones-Hinojosa A; Chaichana KL; Parney IF
    Clin Exp Metastasis; 2020 Apr; 37(2):341-352. PubMed ID: 31950392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.
    Cheng WC; Shen YC; Chien CR; Liao WC; Chen CH; Hsia TC; Tu CY; Chen HJ
    Thorac Cancer; 2022 May; 13(10):1505-1512. PubMed ID: 35394114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.